Ginaasthmamanagement 110401035750-phpapp01


Published on

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Ginaasthmamanagement 110401035750-phpapp01

  1. 1. POCKET GUIDE FOR eASTHMA MANAGEMENT uc AND PREVENTION r od ep (for Adults and Children Older than 5 Years) rr ro lte ta no do l- ria ate dm ® hte rigA Pocket Guide for Physicians and Nurses py Updated 2010Co BASE D ON THE GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
  2. 2. e uc rod ep rr ro lte ta GLOBAL INITIATIVE FOR ASTHMA noExecutive Committee (2010) GINA Assembly (2010) doEric D. Bateman, M.D., South Africa, Chair Louis-Philippe Boulet, MD, Canada, ChairLouis-Philippe Boulet, M.D., Canada l-Alvaro Cruz, M.D., Brazil GINA Assembly members from 45Mark FitzGerald, M.D., Canada Tari countries (names are listed on riaHaahtela, M.D., Finland website: Levy, M.D., United KingdomPaul OByrne, M.D., Canada teKen Ohta, M.D., JapanPierluigi Paggario, M.D., Italy maSoren Pedersen, M.D., DenmarkManuel Soto-Quiroz, M.D., Costa RicaGary Wong, M.D., Hong Kong ROC ted ri gh py © Global Initiative for AsthmaCo This document is protected by copyright. Permission to copy and distribute requires prior approval. Visit for further information.
  3. 3. TABLE OF CONTENTS ePREFACE .......................................................................................2 ucWHAT IS KNOWN ABOUT ASTHMA?...........................................4 r odDIAGNOSING ASTHMA ..............................................................6 Figure 1. Is it Asthma? ........................................................6 epCLASSIFICATION OF ASTHMA BY LEVEL OF CONTROL ...............8 Figure 2. Levels of Asthma Control.........................................8 rrFOUR COMPONENTS OF ASTHMA CARE .....................................9 roComponent 1. Develop Patient/Doctor Partnership..................9 lte Figure 3. Example of Contents of an Action Plan to Maintain Asthma Control....................................................10 taComponent 2. Identify and Reduce Exposure to Risk Factors..11 no Figure 4. Strategies for Avoiding Common Allergens and Pollutants ............................................................11 doComponent 3. Assess, Treat, and Monitor Asthma.................12 Figure 5. Management Approach Based on Control..............14 l- Figure 6. Estimated Equipotent Doses of Inhaled Glucocorticosteroids.............................................15 ria Figure 7. Questions for Monitoring Asthma Care ..................17 ateComponent 4. Manage Exacerbations.....................................18 Figure 8. Severity of Asthma Exacerbations ..........................21 dmSPECIAL CONSIDERATIONS IN MANAGING ASTHMA ..............22Appendix A: Glossary of Asthma Medications - Controllers....23 hteAppendix B: Combination Medications for Asthma ................24Appendix C: Glossary of Asthma Medications - Relievers......25 rig pyCo1
  4. 4. PREFACE e uc r odAsthma is a major cause of chronic morbidity and mortality throughoutthe world and there is evidence that its prevalence has increased epconsiderably over the past 20 years, especially in children. The GlobalInitiative for Asthma was created to increase awareness of asthma rramong health professionals, public health authorities, and the generalpublic, and to improve prevention and management through a concerted roworldwide effort. The Initiative prepares scientific reports on asthma,encourages dissemination and implementation of the recommendations, lteand promotes international collaboration on asthma research. taThe Global Initiative for Asthma offers a framework to achieve andmaintain asthma control for most patients that can be adapted to local nohealth care systems and resources. Educational tools, such as laminatedcards, or computer-based learning programs can be prepared that aretailored to these systems and resources. doThe Global Initiative for Asthma program publications include: l-• Global Strategy for Asthma Management and Prevention (2010). Scientific information and recommendations for asthma programs. ria• Global Strategy for Asthma Management and Prevention ate GINA Executive Summary. Eur Respir J 2008; 31: 1-36• Pocket Guide for Asthma Management and Prevention for Adults and Children Older Than 5 Years (2010). Summary of patient care dm information for primary health care professionals.• Pocket Guide for Asthma Management and Prevention in Children 5 Years and Younger (2009). Summary of patient care information hte for pediatricians and other health care professionals.• What You and Your Family Can Do About Asthma. An information rig booklet for patients and their families. pyPublications are available from Pocket Guide has been developed from the Global Strategy forAsthma Management and Prevention (Updated 2010). Technicaldiscussions of asthma, evidence levels, and specific citations from thescientific literature are included in that source document. 2
  5. 5. Acknowledgements: eGrateful acknowledgement is given for unrestricted educational grants from ucAstraZeneca, Boehringer Ingelheim, Chiesi Group, GlaxoSmithKline, MEDAPharma, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma, Novartis, r odNycomed, and Schering-Plough. The generous contributions of thesecompanies assured that the GINA Committees could meet together andpublications could be printed for wide distribution. However, the GINA epCommittee participants are solely responsible for the statements andconclusions in the publications. rr ro lte ta no do l- ria ate dm hte rig pyCo3
  6. 6. WHAT IS KNOWN eABOUT ASTHMA? uc r odUnfortunately… asthma is one of the most common chronic diseases,with an estimated 300 million individuals affected worldwide. Its epprevalence is increasing, especially among children. rrFortunately… asthma can be effectively treated and most patients canachieve good control of their disease. When asthma is under control ropatients can: lte Avoid troublesome symptoms night and day Use little or no reliever medication ta Have productive, physically active lives Have (near) normal lung function no Avoid serious attacks• Asthma causes recurring episodes of wheezing, breathlessness, do chest tightness, and coughing, particularly at night or in the early morning. l-• Asthma is a chronic inflammatory disorder of the airways. ria Chronically inflamed airways are hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, ate and increased inflammation) when airways are exposed to various risk factors. dm• Common risk factors for asthma symptoms include exposure to allergens (such as those from house dust mites, animals with fur, cockroaches, pollens, and molds), occupational irritants, tobacco smoke, hte respiratory (viral) infections, exercise, strong emotional expressions, chemical irritants, and drugs (such as aspirin and beta blockers). rig• A stepwise approach to pharmacologic treatment to achieve and maintain control of asthma should take into account the safety of py treatment, potential for adverse effects, and the cost of treatment required to achieve control.Co• Asthma attacks (or exacerbations) are episodic, but airway inflammation is chronically present. 4
  7. 7. • For many patients, controller medication must be taken daily to prevent symptoms, improve lung function, and prevent attacks. e Reliever medications may occasionally be required to treat acute uc symptoms such as wheezing, chest tightness, and cough. r od• To reach and maintain asthma control requires the development of a partnership between the person with asthma and his or her health care team. ep• Asthma is not a cause for shame. Olympic athletes, famous leaders, rr other celebrities, and ordinary people live successful lives with asthma. ro lte ta no do l- ria ate dm hte rig pyCo5
  8. 8. DIAGNOSING eASTHMA uc r odAsthma can often be diagnosed on the basis of a patient’s symptomsand medical history (Figure 1). ep Figure 1. Is It Asthma? rr Presence of any of these signs and symptoms should increase the suspicion of asthma: I Wheezing—high-pitched whistling sounds when breathing out—especially in children. ro (A normal chest examination does not exclude asthma.) I History of any of the following: lte • Cough, worse particularly at night • Recurrent wheeze • Recurrent difficult breathing ta • Recurrent chest tightness I Symptoms occur or worsen at night, awakening the patient. no I Symptoms occur or worsen in a seasonal pattern. I The patient also has eczema, hay fever, or a family history of asthma or atopic diseases. do I Symptoms occur or worsen in the presence of: • Animals with fur • Aerosol chemicals l- • Changes in temperature • Domestic dust mites ria • Drugs (aspirin, beta blockers) • Exercise ate • Pollen • Respiratory (viral) infections • Smoke dm • Strong emotional expression I Symptoms respond to anti-asthma therapy. I Patient’s colds “go to the chest” or take more than 10 days to clear up. hteMeasurements of lung function provide an assessment of the severity,reversibility, and variability of airflow limitation, and help confirm the rigdiagnosis of asthma.Spirometry is the preferred method of measuring airflow limitation and pyits reversibility to establish a diagnosis of asthma. • An increase in FEV1 of ≥ 12% and ≥200 ml after administration of aCo bronchodilator indicates reversible airflow limitation consistent with asthma. (However, most asthma patients will not exhibit reversibility at each assessment, and repeated testing is advised.) 6
  9. 9. Peak expiratory flow (PEF) measurements can be an important aid inboth diagnosis and monitoring of asthma. • PEF measurements are ideally compared to the patient’s own previous e best measurements using his/her own peak flow meter. uc • An improvement of 60 L/min (or ≥ 20% of the pre-bronchodilator PEF) after inhalation of a bronchodilator, or diurnal variation in PEF of r od more than 20% (with twice-daily readings, more than 10%), suggests a diagnosis of asthma.Additional diagnostic tests: ep • For patients with symptoms consistent with asthma, but normal lung function, measurements of airway responsiveness to methacho- rr line and histamine, an indirect challenge test such as inhaled manni- ro tol, or exercise challenge may help establish a diagnosis of asthma. • Skin tests with allergens or measurement of specific IgE in serum: The presence of allergies increases the probability of a lte diagnosis of asthma, and can help to identify risk factors that cause asthma symptoms in individual patients. taDiagnostic Challenges no Cough-variant asthma. Some patients with asthma have chronic cough (frequently occurring at night) as their principal, if not only, symptom. For these patients, documentation of lung function variability do and airway hyperresponsiveness are particularly important. Exercise-induced bronchoconstriction. Physical activity is an important cause of asthma symptoms for most asthma patients, and l- for some (including many children) it is the only cause. Exercise testing with an 8-minute running protocol can establish a firm diagnosis of ria asthma. Children 5 Years and Younger. Not all young children who ate wheeze have asthma. In this age group, the diagnosis of asthma must be based largely on clinical judgment, and should be periodically reviewed as the child grows (see the GINA Pocket Guide for Asthma dm Management and Prevention in Children 5 Years and Younger for further details). Asthma in the elderly. Diagnosis and treatment of asthma in the hte elderly are complicated by several factors, including poor perception of symptoms, acceptance of dyspnea as being “normal” for old age, and reduced expectations of mobility and activity. Distinguishing rig asthma from COPD is particularly difficult, and may require a trial of treatment. py Occupational asthma. Asthma acquired in the workplace is a diagnosis that is frequently missed. The diagnosis requires a defined history ofCo occupational exposure to sensitizing agents; an absence of asthma symptoms before beginning employment; and a documented relation- ship between symptoms and the workplace (improvement in symptoms away from work and worsening of symptoms upon returning to work).7
  10. 10. CLASSIFICATION OF ASTHMABY LEVEL OF CONTROL e uc r odThe goal of asthma care is to achieve and maintain control of the clini-cal manifestations of the disease for prolonged periods. When asthma iscontrolled, patients can prevent most attacks, avoid troublesome symptoms epday and night, and keep physically active. rrThe assessment of asthma control should include control of the clinical man-ifestations and control of the expected future risk to the patient such as roexacerbations, accelerated decline in lung function, and side-effects oftreatment. In general, the achievement of good clinical control of asthma lteleads to reduced risk of exacerbations.Figure 2 describes the clinical characteristics of controlled, partly con- tatrolled, and uncontrolled asthma. noFigure 2. LEVELS OF ASTHMA CONTROLA. Assessment of current clinical control (preferably over 4 weeks)Characteristic Controlled Partly Controlled Uncontrolled do (All of the following) (Any measure present)Daytime symptoms None (twice or More than twice/week Three or more features of less/week) partly controlled l- asthma*†Limitation of activities None Any riaNocturnal None Anysymptoms/awakening ateNeed for reliever/ None (twice or More than twice/weekrescue treatment less/week)Lung function (PEF or Normal 80% predicted or dmFEV1)‡ personal best (if known)B. Assessment of Future Risk (risk of exacerbations, instability, rapid decline in lung function, side-effects)Features that are associated with increased risk of adverse events in the future include: htePoor clinical control, frequent exacerbations in past year*, ever admission to critical care for asthma, lowFEV1, exposure to cigarette smoke, high dose medications * Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate † By definition, an exacerbation in any week makes that an uncontrolled asthma week rig ‡ Without administration of bronchodilator, lung function is not a reliable test for children 5 years and youngerExamples of validated measures for assessing clinical control of asthma include: • Asthma Control Test (ACT): py • Childhood Asthma Control test (C-Act)Co • Asthma Control Questionnaire (ACQ): • Asthma Therapy Assessment Questionnaire (ATAQ): • Asthma Control Scoring System 8
  11. 11. FOUR COMPONENTS OF eASTHMA CARE uc r od epFour interrelated components of therapy are required to achieve and main-tain control of asthma rrComponent 1. Develop patient/doctor partnership roComponent 2. Identify and reduce exposure to risk factorsComponent 3. Assess, treat, and monitor asthma lteComponent 4. Manage asthma exacerbations taComponent 1: Develop Patient/Doctor Partnership noThe effective management of asthma requires the development of apartnership between the person with asthma and his or her health care team. doWith your help, and the help of others on the health care team, patientscan learn to: l- • Avoid risk factors ria • Take medications correctly • Understand the difference between “controller” and “reliever” medications ate • Monitor their status using symptoms and, if relevant, PEF • Recognize signs that asthma is worsening and take action dm • Seek medical help as appropriateEducation should be an integral part of all interactions between health htecare professionals and patients. Using a variety of methods—such asdiscussions (with a physician, nurse, outreach worker, counselor, or educa-tor), demonstrations, written materials, group classes, video or audio tapes, rigdramas, and patient support groups—helps reinforce educational messages. pyWorking together, you and your patient should prepare a writtenpersonal asthma action plan that is medically appropriate andCopractical. A sample asthma plan is shown in Figure 3.9
  12. 12. Additional self-management plans can be found on several Websites,including: e r ep Figure 3. Example of Contents of an Action Plan to Maintain Asthma Control rr Your Regular Treatment: ro 1. Each day take ___________________________ 2. Before exercise, take _____________________ lte WHEN TO INCREASE TREATMENT Assess your level of Asthma Control ta In the past week have you had: Daytime asthma symptoms more than 2 times? No Yes Activity or exercise limited by asthma? No Yes no Waking at night because of asthma? No Yes The need to use your [rescue medication] more than 2 times? No Yes If you are monitoring peak flow, peak flow less than______? No Yes do If you answered YES to three or more of these questions, your asthma is uncontrolled and you may need to step up your treatment. l- HOW TO INCREASE TREATMENT STEP UP your treatment as follows and assess improvement every day: ria _________________________________ [Write in next treatment step here] Maintain this treatment for _____________ days [specify number] ate WHEN TO CALL THE DOCTOR/CLINIC. Call your doctor/clinic: _______________ [provide phone numbers] If you don’t respond in _________ days [specify number] dm ____________________________ [optional lines for additional instruction] EMERGENCY/SEVERE LOSS OF CONTROL If you have severe shortness of breath, and can only speak in short sentences, hte If you are having a severe attack of asthma and are frightened, If you need your reliever medication more than every 4 hours and are not improving. rig 1. Take 2 to 4 puffs ___________ [reliever medication] 2. Take ____mg of ____________ [oral glucocorticosteroid] py 3. Seek medical help: Go to ________________; Address______________ Phone: _______________________Co 4. Continue to use your _________ [reliever medication] until you are able to get medical help. 10
  13. 13. Component 2: Identify and Reduce Exposure to RiskFactors e ucTo improve control of asthma and reduce medication needs, patientsshould take steps to avoid the risk factors that cause their asthma symptoms r od(Figure 4). However, many asthma patients react to multiple factors thatare ubiquitous in the environment, and avoiding some of these factors epcompletely is nearly impossible. Thus, medications to maintain asthmacontrol have an important role because patients are often less sensitive tothese risk factors when their asthma is under control. rr roPhysical activity is a common cause of asthma symptoms but patientsshould not avoid exercise. Symptoms can be prevented by taking arapid-acting inhaled ␤2-agonist before strenuous exercise (a leukotriene ltemodifier or cromone are alternatives). taPatients with moderate to severe asthma should be advised to receive aninfluenza vaccination every year, or at least when vaccination of the nogeneral population is advised. Inactivated influenza vaccines are safe foradults and children over age 3. do Figure 4. Strategies for Avoiding Common Allergens and Pollutants l- Avoidance measures that improve control of asthma and reduce medication needs: • Tobacco smoke: Stay away from tobacco smoke. Patients and parents should ria not smoke. • Drugs, foods, and additives: Avoid if they are known to cause symptoms. ate • Occupational sensitizers: Reduce or, preferably, avoid exposure to these agents. Reasonable avoidance measures that can be recommended but have not been shown to have clinical benefit: dm • House dust mites: Wash bed linens and blankets weekly in hot water and dry in a hot dryer or the sun. Encase pillows and mattresses in air-tight covers. Replace carpets with hard flooring, especially in sleeping rooms. (If possible, use hte vacuum cleaner with filters. Use acaricides or tannic acid to kill mites—but make sure the patient is not at home when the treatment occurs.) • Animals with fur: Use air filters. (Remove animals from the home, or at least rig from the sleeping area. Wash the pet.) • Cockroaches: Clean the home thoroughly and often. Use pesticide spray—but py make sure the patient is not at home when spraying occurs. • Outdoor pollens and mold: Close windows and doors and remain indoors when pollen and mold counts are highest.Co • Indoor mold: Reduce dampness in the home; clean any damp areas frequently.11
  14. 14. Component 3: Assess, Treat, and Monitor Asthma eThe goal of asthma treatment—to achieve and maintain clinical control— uccan be reached in most patients through a continuous cycle that involves • Assessing Asthma Control r od • Treating to Achieve Control • Monitoring to Maintain Control epAssessing Asthma Control rrEach patient should be assessed to establish his or her current treatment roregimen, adherence to the current regimen, and level of asthma control.A simplified scheme for recognizing controlled, partly controlled, and lteuncontrolled asthma is provided in Figure 2. taTreating to Achieve Control noEach patient is assigned to one of five treatment “steps.” Figure 5 detailsthe treatments at each step for adults and children age 5 and over. doAt each treatment step, reliever medication should be provided forquick relief of symptoms as needed. (However, be aware of how much l-reliever medication the patient is using—regular or increased use indicates riathat asthma is not well controlled.)At Steps 2 through 5, patients also require one or more regular controller atemedications, which keep symptoms and attacks from starting. Inhaledglucocorticosteroids (Figure 6) are the most effective controller medications dmcurrently available.For most patients newly diagnosed with asthma or not yet on medication,treatment should be started at Step 2 (or if the patient is very symptomatic, hteat Step 3). If asthma is not controlled on the current treatment regimen,treatment should be stepped up until control is achieved. rigPatients who do not reach an acceptable level of control at Step 4 canbe considered to have difficult-to-treat asthma. In these patients, a pycompromise may need to be reached focusing on achieving the best levelof control feasible—with as little disruption of activities and as few dailyCosymptoms as possible—while minimizing the potential for adverse effectsfrom treatment. Referral to an asthma specialist may be helpful. 12
  15. 15. A variety of controller (Appendix A and Appendix B) and reliever(Appendix C) medications for asthma are available. The recommended etreatments are guidelines only. Local resources and individual patient uccircumstances should determine the specific therapy prescribed for eachpatient. r odInhaled medications are preferred because they deliver drugs directly tothe airways where they are needed, resulting in potent therapeutic effects epwith fewer systemic side effects. Inhaled medications for asthma are availableas pressurized metered-dose inhalers (pMDIs), breath-actuated MDIs, dry rrpowder inhalers (DPIs), and nebulizers. Spacer (or valved holding-chamber)devices make inhalers easier to use and reduce systemic absorption and roside effects of inhaled glucocorticosteroids. lteTeach patients (and parents) how to use inhaler devices. Different devicesneed different inhalation techniques. ta • Give demonstrations and illustrated instructions. no • Ask patients to show their technique at every visit. • Information about use of various inhaler devices is found on the GINA Website ( do l- ria ate dm hte rig pyCo13
  16. 16. Figure 5. Management Approach Based On Control Management Approach Based On Control Adults and Children Older than 5 Years For Children Older Than 5 Years, Adolescents and Adults e Reduce uc Level of Control Treatment Action Controlled Maintain and find lowest controlling step r od Partly controlled Consider stepping up to gain control Increase Uncontrolled Step up until controlled ep Exacerbation Treat as exacerbation rr ro Reduce Treatment Steps Increase lte Step 1 Step 2 Step 3 Step 4 Step 5 Asthma education Environmental control ta As needed rapid- As needed rapid-acting β2-agonist acting β2-agonist no To Step 3 treatment, To Step 4 treatment, Select one Select one select one or more add either Medium-or high-dose Low-dose inhaled Low-dose ICS plus Oral glucocorticosteroid ICS plus long-acting ICS* long-acting β2-agonist (lowest dose) β2-agonist do Controller options*** Leukotriene Medium-or Leukotriene Anti-IgE modifier* high-dose ICS modifier treatment l- Low-dose ICS plus Sustained release leukotriene modifier theophylline ria Low-dose ICS plus sustained release theophylline ate * ICS = inhaled glucocorticosteroids **= Receptor antagonist or synthesis inhibitors *** = Preferred controller options are shown in shaded boxes dmAlternative reliever treatments include inhaled anticholinergics, short-acting oral ␤2-agonists,some long-acting ␤2-agonists, and short-acting theophylline. Regular dosing with short andlong-acting ␤2-agonist is not advised unless accompanied by regular use of an inhaled hteglucocorticosteroid. rig pyCo 14
  17. 17. Figure 6. Estimated Equipotent Daily Doses of Inhaled Glucocorticosteroids for Adults and Children Older than 5 Years † e uc Drug ␮ Low Dose (␮g)† ␮ Medium Daily Dose (␮g)† ␮ High Daily Dose (␮g)†Beclomethasone 200-500 500-1000 1000-2000 r oddipropionateBudesonide* 200-400 400-800 800-1600 epCiclesonide* 80-160 160-320 320-1280Flunisolide 500-1000 1000-2000 2000 rrFluticasone 100-250 250-500 500-1000 ropropionateMometasone 200-400 400-800 800-1200furoate* lteTriamcinolone 400-1000 1000-2000 2000acetonide ta no † Comparisons based upon efficacy data. ‡ Patients considered for high daily doses except for short periods should be referred to a specialist for assessment to consider alternative combinations of do controllers. Maximum recommended doses are arbitrary but with prolonged use are associ- ated with increased risk of systemic side effects. * Approved for once-daily dosing in mild patients. l- Notes ria • The most important determinant of appropriate dosing is the clinicians judgment of the patients response to therapy. The clinician must monitor the patients response in terms of clinical control and adjust the dose accordingly. Once control of asthma is achieved, ate the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effects. • Designation of low, medium, and high doses is provided from manufacturers recommen- dm dations where possible. Clear demonstration of dose-response relationships is seldom provided or available. The principle is therefore to establish the minimum effective con- trolling dose in each patient, as higher doses may not be more effective and are likely to be associated with greater potential for adverse effects. hte • As CFC preparations are taken from the market, medication inserts for HFA preparations should be carefully reviewed by the clinician for the equivalent correct dosage. rig pyCo15
  18. 18. Monitoring to Maintain Control eOngoing monitoring is essential to maintain control and establish the uclowest step and dose of treatment to minimize cost and maximize safety. r odTypically, patients should be seen one to three months after the initialvisit, and every three months thereafter. After an exacerbation, follow-upshould be offered within two weeks to one month. epAt each visit, ask the questions listed in Figure 7. rrAdjusting medication: ro • If asthma is not controlled on the current treatment regimen, step up lte treatment. Generally, improvement should be seen within 1 month. But first review the patient’s medication technique, compliance, and ta avoidance of risk factors. • If asthma is partly controlled, consider stepping up treatment, no depending on whether more effective options are available, safety and cost of possible treatment options, and the patient’s satisfaction with the level of control achieved. do • If control is maintained for at least 3 months, step down with a gradual, stepwise reduction in treatment. The goal is to decrease l- treatment to the least medication necessary to maintain control. riaMonitoring is still necessary even after control is achieved, as asthma isa variable disease; treatment has to be adjusted periodically in response ateto loss of control as indicated by worsening symptoms or the developmentof an exacerbation. dm hte rig pyCo 16
  19. 19. Figure 7. Questions for Monitoring Asthma Care e IS THE ASTHMA MANAGEMENT PLAN MEETING EXPECTED GOALS? ucAsk the patient: Action to consider:Has your asthma awakened you atnight? Adjust medications and management r od plan as needed (step up or step down).Have you needed more reliever But first, compliance should bemedications than usual? assessed.Have you needed any urgent medical epcare?Has your peak flow been below your rrpersonal best?Are you participating in your usual rophysical activities? lte IS THE PATIENT USING INHALERS, SPACER, OR ta PEAK FLOW METERS CORRECTLY? noAsk the patient: Action to consider:Please show me how you take yourmedicine. Demonstrate correct technique. Have patient demonstrate back. do IS THE PATIENT TAKING THE MEDICATIONS AND AVOIDING RISK FACTORS ACCORDING TO THE ASTHMA MANAGEMENT PLAN? l-Ask the patient, for example: Action to consider:So that we may plan therapy, please riatell me how often you actually take Adjust plan to be more practical.the medicine. Problem solve with the patient to over- ate come barriers to following the plan.What problems have you had follow-ing the management plan or takingyour medication? dmDuring the last month, have you everstopped taking your medicinebecause you were feeling better? hte rig DOES THE PATIENT HAVE ANY CONCERNS?Ask the patient: Action to consider:What concerns might you have pyabout your asthma, medicines, or Provide additional education to relievemanagement plan? concerns and discussion to overcomeCo barriers.17
  20. 20. Component 4: Manage Exacerbations eExacerbations of asthma (asthma attacks) are episodes of a progressive ucincrease in shortness of breath, cough, wheezing, or chest tightness, or acombination of these symptoms. r odDo not underestimate the severity of an attack; severe asthma epattacks may be life threatening. Their treatment requires close supervision. rrPatients at high risk of asthma-related death require closer attention andshould be encouraged to seek urgent care early in the course of their roexacerbations. These patients include those: lte • With a history of near-fatal asthma requiring intubation and mechanical ventilation ta • Who have had a hospitalization or emergency visit for asthma within the past year no • Who are currently using or have recently stopped using oral gluco- corticosteroids do • Who are not currently using inhaled glucocorticosteroids • Who are overdependent on rapid-acting inhaled ␤2-agnoists, especially l- those who use more than one canister of salbutamol (or equivalent) monthly ria • With a history of psychiatric disease or psychosocial problems, including the use of sedatives ate • With a history of noncompliance with an asthma medication plan dmPatients should immediately seek medical care if: • The attack is severe (Figure 8): hte - The patient is breathless at rest, is hunched forward, talks in words rather than sentences (infant stops feeding), is agitated, rig drowsy, or confused, has bradycardia, or has a respiratory rate greater than 30 per minute py - Wheeze is loud or absent - Pulse is greater than 120/min (greater than 160/min for infants)Co - PEF is less than 60 percent of predicted or personal best, even after initial treatment - The patient is exhausted 18
  21. 21. • The response to the initial bronchodilator treatment is not prompt and sustained for at least 3 hours • There is no improvement within 2 to 6 hours after oral e glucocorticosteroid treatment is started uc • There is further deterioration r odMild attacks, defined by a reduction in peak flow of less than 20%, nocturnalawakening, and increased use of rapid-acting 2-agonists, can usually be eptreated at home if the patient is prepared and has a personal asthmamanagement plan that includes action steps. rr roModerate attacks may require, and severe attacks usually require, care ina clinic or hospital. lteAsthma attacks require prompt treatment: ta • Inhaled rapid-acting 2-agonists in adequate doses are essential. (Begin with 2 to 4 puffs every 20 minutes for the first hour; then mild no exacerbations will require 2 to 4 puffs every 3 to 4 hours, and moderate exacerbations 6 to 10 puffs every 1 to 2 hours.) • Oral glucocorticosteroids (0.5 to 1 mg of prednisolone/kg or equivalent do during a 24-hour period) introduced early in the course of a moderate or severe attack help to reverse the inflammation and speed recovery. l- • Oxygen is given at health centers or hospitals if the patient is hypoxemic (achieve O2 saturation of 95%). ria • Combination 2-agonist/anticholinergic therapy is associated with lower hospitalization rates and greater improvement in PEF and FEV1. ate • Methylxanthines are not recommended if used in addition to high doses of inhaled 2-agonists. However, theophylline can be used if inhaled 2-agonists are not available. If the patient is already taking theophylline dm on a daily basis, serum concentration should be measured before adding short-acting theophylline. • Patients with severe asthma exacerbations unresponsive to bronchodilators hte and systemic glucocorticosteroids, 2 grams of magnesium sulphate IV has been shown to reduce the need for hospitalizations. rigTherapies not recommended for treating asthma attacks include: py • Sedatives (strictly avoid) • Mucolytic drugs (may worsen cough)Co • Chest physical therapy/physiotherapy (may increase patient discomfort) • Hydration with large volumes of fluid for adults and older children (may be necessary for younger children and infants)19
  22. 22. • Antibiotics (do not treat attacks but are indicated for patients who also have pneumonia or bacterial infection such as sinusitis) e • Epinephrine/adrenaline (may be indicated for acute treatment of uc anaphylaxis and angioedema but is not indicated for asthma attacks) r odMonitor response to treatment: epEvaluate symptoms and, as much as possible, peak flow. In the hospital, alsoassess oxygen saturation; consider arterial blood gas measurement inpatients with suspected hypoventilation, exhaustion, severe distress, or peak rrflow 30-50 percent predicted. roFollow up: lteAfter the exacerbation is resolved, the factors that precipitated theexacerbation should be identified and strategies for their future avoidance taimplemented, and the patient’s medication plan reviewed. no do l- ria ate dm hte rig pyCo 20
  23. 23. Figure 8. Severity of Asthma Exacerbations* e Parameter Mild Moderate Severe Respiratory arrest imminent ucBreathless Walking Talking At rest Infant - softer, shorter Infant stops r od cry; difficulty feeding feeding Can lie down Prefer sitting Hunched forwardTalks in Sentences Phrases Words epAlertness May be agitated Usually agitated Usually agitated Drowsy or confused rrRespiratory rate Increased Increased Often 30/min Normal rates of breathing in awake children: Age Normal rate ro 2 months 60/min 2-12 months 50/min lte 1-5 years 40/min 6-8 years 30/minAccessory musclesand suprasternal Usually not Usually ta Usually Paradoxical thoraco-abdominalretractions movement noWheeze Moderate, often Loud Usually loud Absence of only and expiratory wheezePulse/min. 100 100-120 120 Bradycardia do Guide to limits of normal pulse rate in children: Infants 2-12 months -Normal rate 160/min Preschool 1-2 years -Normal rate 120/min l- School age 2-8 years -Normal rate 110/min riaPulsus paradoxus Absent May be present Often present Absence suggests 10 mm Hg 10-25 mm Hg 25 mm Hg (adult) respiratory muscle 20-40 mm Hg (child) fatigue atePEF Over 80% Approx. 60-80% 60% predicted orafter initial personal bestbronchodilator ( 100 L/min adults) dm% predicted or or% personal best response lasts 2 hrsPaO2 (on air)† Normal 60 mm Hg 60 mm Hg Test not usually hte necessary Possible cyanosisand/orpaCO2† 45 mm Hg 45 mm Hg 45 mm Hg; Possible respiratory failure (see text) rigSaO2% (on air)† 95% 91-95% 90% py Hypercapnia (hypoventilation) develops more readily in young children than in adults and adolescents.*Note: The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation.Co†Note: Kilopascals are also used internationally, conversion would be appropriate in this regard.21
  24. 24. SPECIAL CONSIDERATIONS eIN MANAGING ASTHMA uc r od Pregnancy. During pregnancy the severity of asthma often changes, and patients may require close follow-up and adjustment of medications. Pregnant ep patients with asthma should be advised that the greater risk to their baby lies with poorly controlled asthma, and the safety of most modern asthma treatments should be stressed. Acute exacerbations should be treated rr aggressively to avoid fetal hypoxia. Obesity. Management of asthma in the obese should be the same as patients ro with normal weight. Weight loss in the obese patient improves asthma control, lung function and reduces medication needs. lte Surgery. Airway hyperresponsiveness, airflow limitation, and mucus hyper- secretion predispose patients with asthma to intraoperative and postoperative ta respiratory complications, particularly with thoracic and upper abdominal surgeries. Lung function should be evaluated several days prior to surgery, and a brief course of glucocorticosteroids prescribed if FEV1 is less than no 80% of the patient’s personal best. Rhinitis, Sinusitis, and Nasal Polyps. Rhinitis and asthma often coexist in the same patient, and treatment of rhinitis may improve asthma symptoms. do Both acute and chronic sinusitis can worsen asthma, and should be treated. Nasal polyps are associated with asthma and rhinitis, often with aspirin sensitivity and most frequently in adult patients. They are normally quite l- responsive to topical glucocorticosteroids. Occupational asthma. Pharmacologic therapy for occupational asthma ria is identical to therapy for other forms of asthma, but is not a substitute for adequate avoidance of the relevant exposure. Consultation with a specialist in ate asthma management or occupational medicine is advisable. Respiratory infections. Respiratory infections provoke wheezing and increased asthma symptoms in many patients. Treatment of an infectious dm exacerbation follows the same principles as treatment of other exacerbations. Gastroesophageal reflux. Gastroesophageal reflux is more common in patients with asthma compared to the general population. However, treatment with proton pump inhibitors, H2 antagorists or surgery fail to improve asthma hte control. Aspirin-induced asthma. Up to 28 percent of adults with asthma, but rarely children, suffer from asthma exacerbations in response to aspirin rig and other nonsteroidal anti-inflammatory drugs. The diagnosis can only be confirmed by aspirin challenge, which must be conducted in a facility withpy cardiopulmonary resuscitation capabilities. Complete avoidance of the drugs that cause symptoms is the standard management.CoAnaphylaxis. Anaphylaxis is a potentially life-threatening condition that canboth mimic and complicate severe asthma. Prompt treatment is crucial andincludes oxygen, intramuscular epinephrine, injectable antihistamine,intravenous hydrocortisone, and intravenous fluid. 22
  25. 25. Appendix A: Glossary of Asthma Medications - Controllers Name and Usual Doses Side Effects Comments eAlso Known As ucGlucocortico- Inhaled: Beginning Inhaled: High daily doses Inhaled: Potential but smallsteroids dose dependent on may be associated with skin risk of side effects is wellAdrenocorticoids asthma control then thinning and bruises, and balanced by efficacy. Valved r odCorticosteroids titrated down over rarely adrenal suppression. holding-chambers with MDIsGlucocorticoids 2-3 months to lowest Local side effects are hoarse- and mouth washing with DPIs effective dose once ness and oropharyngeal after inhalation decrease oralInhaled (ICS): control is achieved. candidiasis. Low to medium Candidiasis. Preparations not epBeclomethasone doses have produced minor equivalent on per puff or ␮gBudesonide growth delay or suppression basis.Ciclesonide Tablets or syrups: (av. 1cm) in children. AttainmentFlunisolide For daily control use of predicted adult height does rrFluticasone lowest effective dose not appear to be affected. Tablet or syrup: LongMometasone 5-40 mg of prednisone term use: alternate day a.m.Triamcinolone equivalent in a.m. or dosing produces less toxicity. ro qod. Tablets or syrups: Used Short term: 3-10 day “bursts”Tablets or syrups: long term, may lead to are effective for gaininghydrocortisone For acute attacks osteoporosis, hypertension, prompt control.methylprednisolone lte 40-60 mg daily in diabetes, cataracts, adrenalprednisolone 1 or 2 divided doses suppression, growth suppression,prednisone for adults or 1-2 mg/kg obesity, skin thinning or muscle daily in children. weakness. Consider coexisting ta conditions that could be worsened by oral glucocortico- steroids, e.g. herpes virus no infections, Varicella, tuberculosis, hypertension, diabetes and osteoporosis doSodium MDI 2 mg or 5 mg Minimal side effects. Cough May take 4-6 weeks tocromoglycate 2-4 inhalations 3-4 may occur upon inhalation. determine maximum effects.cromolyn times daily. Nebulizer Frequent daily dosingcromones 20 mg 3-4 times daily. required. l-Nedocromil MDI 2 mg/puff 2-4 Cough may occur upon Some patients unable to riacromones inhalations 2-4 times inhalation. tolerate the taste. daily. ateLong-acting Inhaled: Inhaled: fewer, and less Inhaled: Salmeterol NOT to␤2-agonists DPI -F: 1 inhalation significant, side effects than be used to treat acute attacks.beta-adrenergis (12 ␮g) bid. tablets. Have been associated Should not use as mono-sympathomimetics MDI- F: 2 puffs bid. with an increased risk of therapy for controller therapy. dmLABAs DPI-Sm: 1 inhalation severe exacerbations and Always use as adjunct to (50 ␮g) bid. asthma deaths when added ICS therapy. Formoterol hasInhaled: MDI-Sm: 2 puffs bid. to usual therapy. onset similar to salbutamolFormoterol (F) and has been used as neededSalmeterol (Sm) for acute symptoms. hte Tablets: Tablets: may causeSustained-release S: 4 mg q12h. tachycardia, anxiety, skeletal Tablets: As effective asTablets: T: 10mg q12h. muscle tremor, headache, sustained-release theophylline.Salbutamol (S) hypokalemia. No data for use as adjunctive rigTerbutaline (T) Starting dose 10 therapy with inhaledAminophylline mg/kg/day with Nausea and vomiting are glucocorticosteroids.methylxanthine usual 800 mg most common. Serious effectsxanthine maximum in occurring at higher serum Theophylline level monitoring py 1-2 divided doses. concentrations include is often required. Absorption seizures, tachycardia, and and metabolism may be arrhythmias. affected by many factors,Co including febrile illness. Table continued...23
  26. 26. Appendix A: Glossary of Asthma Medications - Controllers (continued...) Name and Usual Doses Side Effects Comments Also Known As e ucAntileukotrienes Adults: M 10mg qhs No specific adverse effects Antileukotrienes are mostLeukotriene modifiers P 450mg bid to date at recommended effective for patients withMontelukast (M) Z 20mg bid; doses. Elevation of liver mild persistent asthma. They enzymes with Zafirlukast provide additive benefit when r odPranlukast (P) Zi 600mg qid.Zafirlukast (Z) and Zileuton and limited added to ICSs though not asZileuton (Zi) Children: M 5 mg case reports of reversible effective as inhaled long-acting qhs (6-14 y) hepatitis and hyperbiliru- 2-agonists. M 4 mg qhs (2-5 y) binemia with Zileuton and ep Z 10mg bid (7-11 y). hepatic failure with afirlukastImmunomodulators Adults: Dose Pain and bruising at injec- Need to be stored under rrOmalizumab administered subcu- tion site (5-20%) and very refrigeration 2-8˚C andAnti-IgE taneously every 2 or 4 rarely anaphylaxis (0.1%). maximum of 150 mg weeks dependent administered per injection site. ro on weight and IgE concentration lte Appendix B: Combination Medications For Asthma ta Formulation Inhaler Devices Doses Inhalations/day Therapeutic Available Use ( g)1 ICS/LABA no Fluticasone DPI 100/501 1 inhalation x 2 Maintenance propionate/ 250/50 salmeterol 500/50 do Fluticasone pMDI 50/251 2 inhalations x 2 Maintenance propionate/ (Suspension) 125/25 salmeterol 250/25 l- Budesonide/ DPI 80/4.52 1-2 inhalations x 2 Maintenance formoterol 160/4.5 and Relief ria 320/9.0 Budesonide/ pMDI 80/4.52 2 inhalations x 2 Maintenance ate formoterol (Suspension) 160/4.5 Beclomethasone/ pMDI 100/63 1-2 inhalations x 2 Maintenance formoterol (Solution) dm Mometasone/ pMDI 100/5 2 inhalations x 2 Maintenance formoterol 200/5 hteICS = inhaled corticosteroid; LABA = long acting -agonist; pMDI = pressurized metered dose inhaler; DPI = dry powder inhaler 2New formulations will be reviewed for inclusion in the table as they are approved. Such medications may bebrought to the attention of the GINA Science Committee. rig1 Refers to metered dose. For additional information about dosages and products available in specificcountries, please consult to find a link to your country website or contact your local company pyrepresentatives for products approved for use in your country.2 Refers to delivered dose. For additional information about dosages and products available in specificCocountries, please consult to find a link to your country website or contact yourlocal company representatives for products approved for use in your country.3 Refers to metered dose. For additional information about dosages and products available in specificcountries, please consult to find a link to your country website or contact yourlocal company representatives for products approved for use in your country. 24
  27. 27. Appendix C: Glossary of Asthma Medications - Relievers eName and Also Usual Doses Side Effects Comments Known As ucShort-acting Differences in potency Inhaled: tachycardia, Drug of choice for acute␤2-agonists exist but all products skeletal muscle tremor, bronchospasm. Inhaled route r odAdrenergics are essentially headache, and irritability. has faster onset and is more␤2-stimulants comparable on a per At very high dose hyper- effective than tablet or syrup.Sympathomimetics puff basis. For pre glycemia, hypokalemia. Increasing use, lack of expected symptomatic use and effect, or use of 1 canisterAlbuterol/salbutamol pretreatment before Systemic administration as a month indicate poor asthma epFenoterol exercise 2 puffs MDI Tablets or Syrup increases control; adjust long-termLevalbuterol or 1 inhalation DPI. the risk of these side effects. therapy accordingly. UseMetaproterenol For asthma attacks of 2 canisters per month is rrPirbuterol 4-8 puffs q2-4h, may associated with an increasedTerbutaline administer q20min x 3 risk of a severe, life-threatening with medical supervi- asthma attack. ro sion or the equivalent of 5 mg salbutamol by nebulizer. lteAnticholinergics IB-MDI 4-6 puffs q6h or Minimal mouth dryness or May provide additive effectsIpratropium q20 min in the emergency bad taste in the mouth. to ␤2-agonist but has slower bromide (IB) department. Nebulizer ta onset of action. Is an alternativeOxitropium 500 ␮g q20min x 3 for patients with intolerance bromide then q2-4hrs for adults for ␤2-agonists. and 250-500 ␮g for no children.Short-acting 7 mg/kg loading Nausea, vomiting, headache. Theophylline level monitoringtheophylline dose over 20 min At higher serum concentra- is required. Obtain serumAminophylline followed by 0.4 tions: seizures, tachycardia, levels 12 and 24 hours into do mg/kg/hr continuous and arrhythmias. infusion. Maintain between infusion. 10-15 ␮g/mL.Epinephrine/ 1:1000 solution Similar, but more significant In general, not recommended l-adrenaline (1mg/mL) .01mg/kg effects than selective ␤2-agonist. for treating asthma attacks ifinjection up to 0.3-0.5 mg, can In addition: hypertension, selective ␤2-agonists are give q20min x 3. fever, vomiting in children and available. ria hallucinations. ate dm hte rig pyCo25
  28. 28. Co py rig NOTES hte dm ate ria l- do no ta lte ro rr ep r od uc e26
  29. 29. 27 Co py rig NOTES hte dm ate ria l- do no ta lte ro rr ep r od uc e
  30. 30. The Global Initiative for Asthma is supported by educational grants from: e uc r od ep rr ro lte ta no do l- ria ate dm hte rig py Visit the GINA website at www.ginasthma.orgCo bc30 Copies of this document are available at